Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG

Kinarus Therapeutics Holding AG / Key word(s): Acquisition/Insolvency Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG 06-Feb-2024 / 07:10 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, ITALY, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Basel, Switzerland, 6 February 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company has been informed on 5 February 2024 that the courts of Basel-Stadt have revoked the bankruptcy of Kinarus Holding.

The revocation of bankruptcy is one of the conditions for the consummation of the business combination contemplated by the transaction agreement signed by Kinarus Holding and Curatis AG, as announced and further described in the press release dated 29 January 2024 ("Press Release").

Furthermore, Kinarus Holding has scheduled an Extraordinary General Meeting for Friday, 1 March 2024 to propose the resolutions required for the business combination with Curatis AG and to propose Ernst & Young AG to be elected as the Company's statutory auditor. The respective invitation will be disseminated on Thursday, 8 February 2024.

Also, Kinarus Holding has mandated Reyl & Cie SA as Paying Agent for the reverse share split in the ratio of 4,480:1 and the settlement of the business combination between Kinarus Holding and Curatis AG expected to be implemented in Q2 2024.

About Kinarus Therapeutics Holding AG

Kinarus AG in Liquidation (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus Group consists of the SIX Swiss Exchange listed Kinarus Therapeutics Holding AG and the operating fully owned subsidiary Kinarus AG in Liquidation. Both Kinarus Therapeutics Holding AG and Kinarus AG in Liquidation have filed for bankruptcy in September 2023 after a financing agreement with a Chinese investment company in May 2023 has not led to the agreed payments. Kinarus AG in Liquidation possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.